Unknown

Dataset Information

0

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults.

ABSTRACT:

SUBMITTER: Liu X 

PROVIDER: S-EPMC9197092 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
| S-EPMC7556339 | biostudies-literature
Unknown Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
| S-EPMC8786321 | biostudies-literature
Unknown Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
| S-EPMC8604720 | biostudies-literature
Unknown Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
| S-EPMC2694271 | biostudies-literature
Unknown A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.
| S-EPMC7403570 | biostudies-literature
Unknown Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
| S-EPMC8346248 | biostudies-literature
Unknown The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.
| S-EPMC8057239 | biostudies-literature
Unknown Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
| S-EPMC8381941 | biostudies-literature
Unknown Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
| S-EPMC8557105 | biostudies-literature
Unknown Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection.
| S-EPMC8471735 | biostudies-literature